This new class of HCV drugs, which are much easier on the human body and virtually free of side effects, attacks the virus directly and can reduce the viral load to zero when taken correctly.
There is a raging debate going on in Washington about how the government pays for drugs used to treat cancer, rheumatoid arthritis, immunodeficiency diseases, and other serious medical conditions.
An Obama initiative to hold the line on spending has run into a lobbying buzzsaw.